Edition:
United Kingdom

Sellas Life Sciences Group Inc (SLS.OQ)

SLS.OQ on NASDAQ Stock Exchange Capital Market

5.30USD
26 Apr 2018
Change (% chg)

$-0.16 (-2.93%)
Prev Close
$5.46
Open
$5.39
Day's High
$5.59
Day's Low
$5.15
Volume
9,014
Avg. Vol
82,225
52-wk High
$19.74
52-wk Low
$3.43

Chart for

About

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunothera... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $32.99
Shares Outstanding(Mil.): 6.57
Dividend: --
Yield (%): --

Financials

  SLS.OQ Industry Sector
P/E (TTM): -- 29.67 32.21
EPS (TTM): -14.51 -- --
ROI: -493.90 13.44 13.05
ROE: -- 15.16 14.90

BRIEF-Sellas Life Sciences Ceases Gregory Torre's Employment As Chief Regulatory Officer

* SELLAS LIFE SCIENCES GROUP- ON APRIL 19, CO AND GREGORY TORRE, AGREED THAT HIS EMPLOYMENT AS CHIEF REGULATORY OFFICER WOULD CEASE - SEC FILING

24 Apr 2018

BRIEF-Sellas Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer & Treasurer

* SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER

20 Apr 2018

BRIEF-Sellas Life Sciences Announces Positive Interim Data From Phase 2B Neuvax Clinical Trial In Combination With Herceptin

* SELLAS LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B NEUVAX™ (NELIPEPIMUT-S) CLINICAL TRIAL IN COMBINATION WITH HERCEPTIN® IN HER2 1+/2+ BREAST CANCER PATIENTS

02 Apr 2018

BRIEF-Sellas Life Sciences Announces $10.7 Mln Private Placement

* SELLAS LIFE SCIENCES ANNOUNCES $10,700,000 PRIVATE PLACEMENT

07 Mar 2018

Earnings vs. Estimates